Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7760 · 2 trials · 2 indications
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.
To evaluate the safety of AZD7760 compared with placebo as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (AZD7760 Dose A) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose A on Day 1. |
| Cohort 2 (AZD7760 Dose B) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose B on Day 1. |
| Pooled Placebo | PLACEBO_COMPARATOR | Participants receive an IV infusion of matching placebo on Day 1. |
| Phase I: AZD7760 Dose A | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1. |
| Phase I: AZD7760 Dose B | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1. |
| Phase I: AZD7760 Dose C | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1. |
| Phase I: Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo on Day 1. |
| Phase IIa: AZD7760 Dose D and Placebo | EXPERIMENTAL | Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91. |
| Phase IIa: AZD7760 Dose E | EXPERIMENTAL | Participants will receive AZD7760 Dose E on Day 1 and Day 91. |
| Phase IIa: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo on Day 1 and on Day 91. |
| Name | Type | Description |
|---|---|---|
| AZD7760 | DRUG | Participants will receive AZD7760 via IV infusion. |
| Placebo | OTHER | Participants will receive matching placebo via IV infusion. |
Inclusion Criteria: * Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range of ≥ 18.0 to ≤ 30.0 kg/m2 (inclusive) at screening. * Healthy Japanese participants with no clinically significant concomitant diseases or medications. Exclusion Criteria: * Known hypersensitivity to any component of ...
AZD7760 is an investigational small molecule being developed for Staphylococcus aureus bloodstream infection and Staphylococcus aureus. It is being studied in healthy adults and in adults with end-stage kidney disease on hemodialysis with a central venous catheter.
AZD7760 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials of the drug in the United States and Japan.
AZD7760 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials are currently recruiting participants.
AZD7760 is a small molecule being studied for its activity against Staphylococcus aureus, including bloodstream infections. Its specific molecular target has not been disclosed in the available clinical trial information.
AZD7760 is being evaluated in two Phase 1 trials. NCT06749457 is a randomized, double-blind, placebo-controlled study in healthy adults and adults with end-stage kidney disease on hemodialysis, with an enrollment of 231. NCT07612813 is a study in healthy Japanese adults with an enrollment of 18.
AZD7760 is the primary name used in clinical trials for this investigational drug. No alternative names have been reported in the available clinical trial information.